Skip to main content

Paragon 28, Inc. (FNA)

NYSE: FNA · IEX Real-Time Price · USD
18.90 -0.05 (-0.26%)
Oct 27, 2021 11:40 AM EDT - Market open
Market Cap1.42B
Revenue (ttm)134.16M
Net Income (ttm)5.56M
Shares Out75.20M
EPS (ttm)0.07
PE Ratio255.54
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,226
Open18.97
Previous Close18.95
Day's Range18.80 - 19.04
52-Week Range17.26 - 19.92
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About FNA

Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. Our innovative orthopedic solutions, procedural approaches and instrumentation cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, we provide a comprehensive portfolio...

IndustryMedical Devices
IPO DateOct 15, 2021
CEOAlbert DaCosta
Employees295
Stock ExchangeNYSE
Ticker SymbolFNA
Full Company Profile

Financial Performance

In 2020, Paragon 28's revenue was $110.98 million, an increase of 4.42% compared to the previous year's $106.28 million. Earnings were $3.50 million, an increase of 12.22%.

Financial Statements

News

Paragon 28, Inc. Announces Pricing of Initial Public Offering

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,81...

1 week ago - Business Wire

Paragon 28 IPO Registration Document (S-1)

Paragon 28, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

1 month ago - SEC